

**ORAL PRESENTATION**

**Open Access**

# Anti-tumor antibody profile analysis to harness the potentials of B cells in melanomas and the natural humoral immune response

Beatrix Kotlan<sup>1\*</sup>, Gabriella Liszkay<sup>2,8,9</sup>, Miri Blank<sup>3</sup>, Judit Olasz<sup>4</sup>, Orsolya Csuka<sup>4,8</sup>, Timea Balatoni<sup>2</sup>, Kinga Borbola<sup>2</sup>, Laszlo Toth<sup>5</sup>, Gyorgy Naszados<sup>6</sup>, Francesco M Marincola<sup>7</sup>, Maria Godeny<sup>6,8,9</sup>, Miklos Kasler<sup>8,9</sup>, Yehuda Shoenfeld<sup>3</sup>

From Society for Immunotherapy of Cancer 28th Annual Meeting  
National Harbor, MD, USA. 8-10 November 2013


## Objectives

Natural humoral immune response and autoimmune mechanisms have great importance in keeping the balance of tumorimmunity, although it has not yet been fully understood. We aimed to reveal potential anti-tumor immune response by immunoglobulin (Ig) profile analysis of patients with metastatic melanomas.


## Methods

A complex panel assay has been performed at expressed DNA and protein levels on antibodies originating from patients' peripheral blood (n = 92) or cancerous tissue biopsies (n= 87) (ETT TUKEB 16462- 02/2010). Heavy and light chain immunoglobulin variable gene regions were sequenced and analysed with Vector NTI Advance

**a/**



**b/**



**Figure 1** Human purified immunoglobulin of patient (a) and antibody fragments developed (b/) show cancer associated antigen specific binding on SK-Mel 28 cells and melanoma tissues.

<sup>1</sup>Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary

Full list of author information is available at the end of the article

11, Bioedit 7.0, ClustalX2.0.11, TreeView 1.6.6 programs using available databases (IMGT, Blast). Patients' sera, purified human Ig preparations and antibody fragments from tumor infiltrating B cells were tested by ELISA, immunofluorescence FACS and confocal laser microscopy.

## Results

Cluster analysis revealed specific antibody variable region gene subgroups in the VH3 family, amongst which there are the ones with cancer associated antigen binding capacity. The purified immunoglobulin's strong SK-Mel28 melanoma binding potential paralleled with the clinical outcome. Some selected expressed antibody fragments showed tumor associated antigen labelling on melanoma tissues (Fig. 1). A competitive cell membrane ELISA has been standardized for measuring patients' sera in terms of various cancer associated antigen binding capacity. Data are under evaluation concerning their value to predict anti cancer humoral immune response.

## Conclusions

We could prove the extensive presence of highly tumor associated unique GD3 sialilated glycosphingolipid specific antibody variable regions in patients with melanoma. Our novel panel assay confirmed the potentials of antibody profile analysis in characterizing anti tumor humoral immune response and its worth for diagnostics.

## Acknowledgement

The Harry J. Lloyd Charitable Trust Melanoma Research Foundation Award and previous Fulbright No1206103 and OTKA T048933 Grants are acknowledged.

## Authors' details

<sup>1</sup>Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary. <sup>2</sup>Oncodermatology, National Institute of Oncology, Budapest, Hungary. <sup>3</sup>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel. <sup>4</sup>Pathogenetics, National Institute of Oncology, Budapest, Hungary. <sup>5</sup>Oncosurgery, National Institute of Oncology, Budapest, Hungary. <sup>6</sup>Radiological Diagnostics, National Institute of Oncology, Budapest, Hungary. <sup>7</sup>SLDRA Medical and Research Center, Doha, Qatar. <sup>8</sup>Board of Directors, National Institute of Oncology, Budapest, Hungary. <sup>9</sup>Univ Med Pharm, Tîrgu Mureş, Romania.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-O4

**Cite this article as:** Kotlan et al.: Anti-tumor antibody profile analysis to harness the potentials of B cells in melanomas and the natural humoral immune response. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):O4.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

